Feed / NVCR

NovoCure Limited

NVCR

Healthcare · 18.49 +14.9% today

Partial group confirmationMarket checked 20 Aug, 09:30 GMT-4

Jodie situation report

NovoCure Limited's move is being confirmed by its market group.

NVCR accounts for 12.1% of the group's measured movement across 1.4 effective names. raw member direction is mixed; 2 of 3 session-normalized paths align to the upside. Capital-flow agreement is 21%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveAligned contributor#2 of 3 by movement share
Group movement share12.1%Absolute path energy—not portfolio weight
Relative path+1.59%aligned
Effective breadth1.4 / 3concentrated
Relative alignment2/3upside path · 1 counter-moving
Capital-flow agreement21%not yet clean
SEQUENCE READ

DCTH moved materially before NVCR. NVCR crossed its material path threshold at 10:15 ET, 15 minutes after the first measured mover. ACHV followed.

EVIDENCE COVERAGE

3 of 3 members in Cancer and Nicotine Therapies are active. 0 of 5 disclosed connections are confirming.

What would change this read
  • At least 2 of 3 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as CADL begins moving with the group.

Invalidation: The live read weakens if participation falls to 1 of 3 members or fewer.

Watch this read

Who this business touches

The relationships behind NVCR

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ZLABZai Lab LimitedpartnerApr 30, 2026 ▾

“In 2018, we granted Zai Lab (Shanghai) Co., Ltd.”

MRKMerck & Company, Inc.partnerFeb 26, 2026 ▾

“KEYNOTE D58 was designed and is being conducted as part of a clinical collaboration between Novocure and MSD, a tradename of Merck & Co., Inc.”

Depended on by

ZLABZai Lab LimitedpartnerAug 7, 2025 ▾

“Tumor Treating Fields (TTFields): In May 2025, our partner NovoCure presented results from the Phase III PANOVA-3 trial of TTFields therapy for pancreatic cancer at the 2025 ASCO Annual Meeting and simultaneously published in the Journal of Clinical Oncology.”

Filing peers

IOVA

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

NVCR is currently a Early Follower in the organic co-movement group Cancer and Nicotine Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.